Novartis AG

Novartis AG

159.13
USD
-1.07
(-0.67%)
5.18EPS
27.32P/E
271.54BMarket Cap
Feb 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
21.42
21.92
20.79
20.61
18.35
19.71
21.07
21.73
19.44
19.76
22.28
25.42
28.98
29.85
Basic EPS, GAAP
3.73
4.17
7.34
2.8
3.26
5.39
5.08
3.52
10.62
3.16
7.09
5.87
7.15
5.22
Free Cash Flow per Basic Share
3.98
4.29
3.46
3.58
4.37
4.97
4.92
4.82
5.53
5.45
5.59
6.78
7.8
7.29
Dividend per Share
2.48
2.78
2.74
2.7
2.75
2.98
2.88
3.04
3.26
3.41
3.46
3.75
4
4.72
Book Value per Share
30.39
29.26
32.18
31.26
31.74
33.73
24.29
24.87
30.02
27.76
22.64
22.11
23.97
19.55
Tangible Book Value per Share
6.33
7.29
4.87
5.23
5.31
1.97
0.07
-4.49
1.72
-0.75
-1.72
-3.83
-4.6
-15.63
Basic Weighted Avg Shares
2,462
2,447
2,423
2,398
2,366
2,339
2,310
2,296
2,262
2,199
2,094
2,035
1,955
1,922
Sales/Revenue/Turnover
52,716
53,634
50,387
49,436
43,404
46,099
48,677
49,898
43,974
43,461
46,660
51,722
56,674
57,364
Operating Margin (%)
20.83
20.68
17.82
16.72
20.05
18.23
18.67
20.35
22.87
18.28
20.94
28.12
31.13
25.18
Depreciation Expense
4,405
4,682
5,471
6,043
4,736
5,211
5,826
6,464
5,597
6,705
8,277
6,069
5,325
7,759
Net Income, GAAP
9,175
10,210
17,783
6,712
7,703
12,611
11,732
8,072
24,021
6,955
14,850
11,941
13,984
10,031
Effective Tax Rate (%)
13.86
12.59
13.6
14.31
17.61
9.19
20.06
18.29
6.62
15.72
6.04
12.47
14.59
20.8
Profit Margin (%)
17.4
19.04
35.29
13.58
17.75
27.36
24.1
16.18
54.63
16
31.83
23.09
24.67
17.49
Working Capital
4,174
10,588
-863
2,722
4,805
5,956
1,240
-3,386
15,510
8,254
4,091
1,012
3,182
-3,778
LT Debt
11,242
13,799
16,327
17,897
23,224
22,470
22,056
27,978
24,523
21,782
20,034
22,934
29,592
38,382
Total Equity
74,472
70,844
77,122
74,891
74,227
78,692
55,551
56,666
67,822
59,423
46,750
44,126
46,549
37,564
Return on Invested Capital (%)
10.14
10.26
7.96
7.02
6.98
7
7.25
8.97
9.42
6.96
11.05
16.64
18.61
13.57
Return on Capital (%)
10.64
11.72
19.29
7.42
8.27
12.61
12.69
9.8
25.61
8.2
19.51
17.27
19.04
13.89
Return on Common Equity (%)
12.79
14.07
24.06
8.84
10.34
16.51
17.5
14.41
38.66
10.95
28.02
26.33
31.01
24.6

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
7,888
9,862
9,928
LT Borrowings
37,447
37,489
36,699
LT Finance Leases
1,663
1,663
1,683
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,924
1,917
1,905
Market Capitalization
293,925
300,398
271,538

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
26,607
27,351
28,747
Cash, Cash Equivalents & STI
6,977
7,690
8,975
Accounts Receivable, Net
9,386
9,636
9,780
Inventories
6,286
6,220
6,104
Total Current Liabilities
31,374
31,748
32,525
Payables & Accruals
6,129
6,570
6,895
ST Debt
7,888
9,862
9,928
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.93%
-2.83%
5.49%
Free Cash Flow
6.52%
6.98%
10.42%
Net Income, GAAP
21.56%
47.51%
17.11%
Sales/Revenue/Turnover
1.5%
2.95%
9.57%
Total Cash Common Dividend
1.72%
2.32%
2.54%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,120
12,872
13,172
13,558
51,722
2025
13,620
14,836
14,358
13,860
56,674
2026
13,524
14,951
15,029
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.58
1.57
1.41
5.87
2025
1.82
2.06
2.04
1.25
7.15
2026
1.64
1.7
0.63
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.53
1.18
- -
- -
3.75
2025
2.69
1.26
- -
- -
4
2026
3.22
1.49
- -
- -
- -

Company Description

CEO
Vasant Narasimhan
Full Time Employees
75,267
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Lichtstrasse 35 Basel BS Switzerland 4056
IPO Date
May 7, 2001
Business
Novartis AG is dedicated to the worldwide discovery, advancement, production, and distribution of pioneering healthcare solutions. The enterprise now operates exclusively as an innovative medicines company, having concluded the full divestiture of its Sandoz generics and biosimilars business in October 2023. Its focused efforts encompass key therapeutic areas, including cardiovascular, renal, and metabolic diseases, immunology, neuroscience, and oncology, striving to address significant global patient needs. Within these domains, Novartis offers a suite of advanced therapies such as Kisqali for breast cancer, Kesimpta for multiple sclerosis, Pluvicto for prostate cancer, and Scemblix for chronic myeloid leukemia, in addition to products like Cosentyx, Leqvio, Fabhalta, and Rhapsido for chronic spontaneous urticaria. The company strategically expands its pipeline through acquisitions and partnerships, evidenced by an increased investment and collaboration with Argo Biopharma on RNA interference therapies for cardiovascular conditions, the acquisition of MorphoSys AG to enhance its oncology offerings, and plans for substantial expansion of its manufacturing footprint in the United States. Novartis AG was established in 1996 and is headquartered in Basel, Switzerland.

Company News

  • Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

  • Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HS

  • Is Novartis (NVS) Outperforming Other Medical Stocks This Year?

  • Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice

  • Commonwealth Equity Services LLC Purchases 3,997 Shares of Novartis AG $NVS

  • 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026

  • Novartis: 3 Key Takeaways for Long-Term Investors

  • 3 Stocks to Watch Following Guidance Upgrades

  • BioArctic collaborator Novartis terminates agreement

  • 6 dividend stocks for investors who want to cut their exposure to the S&P 500

  • Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

  • Companies promised AI gains— here's how the payoff showed up in earnings

  • Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach

  • All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

  • Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

  • A pharma giant is moving past one patent cliff — but another is already looming

  • Novartis AG (NVS) Q3 2026 Earnings Call Transcript

  • These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

  • What Novartis (NVS) Said on Its Q3 Earnings Call

  • 4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential